InnoCare Pharma (SHA:688428, HKG:9969) recorded an attributable loss of 34.3 million yuan in the third quarter of 2025, a Thursday Hong Kong bourse filing said.

Loss per share for the three months stood at 0.02 yuan, with operating revenue rising 38% to 383.9 million yuan.

The higher revenue was due to an increase in the sales revenue of core product orelabrutinib, as well as the upfront payment under an exclusive license agreement with Prolium Bioscience.

For the nine months ended Sept. 30, attributable loss reached 64.4 million yuan, while operating revenue surged 60% to 1.12 billion yuan.